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The inverse relationship previously demonstrated be-
tween myocyte volume derangement and contractility in iso-
lated myocytes suggested loss of myocyte volume
homeostasis as a potential mechanism of myocardial stun-
ning.4 The ability of DZX to prevent myocyte swelling
and resultant contractile dysfunction secondary to 3 inde-
pendent stresses in 3 species suggests that its use may be ex-
ploited for the reduction of myocardial stunning. Elucidation
of the mechanism of action of DZX in the mouse at the
cellular and subcellular levels will subsequently facilitate
its acceptance and use at the clinical level.
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Dr Friedhelm Beyersdorf (Freiburg, Germany). Swelling of
cardiomyocytes is an important aspect of ischemia–reperfusion in-
jury of the heart that leads to impaired myocardial function. You
simulate ischemia in your experiments by MI using a specific solu-
tion. I have 2 questions for you:
First, you showed that a current in the ATP-sensitive potassium
channels is not induced by CPG but by MI. However, both condi-
tions lead to cardiomyocyte swelling. In contrast, again, only swell-
ing caused by MI is prevented by DZX. Could you comment on
possible differences between these 2 experimental conditions?
Ms Sellitto. The hyperkalemic CPG is more of a hypo-osmotic
stress as opposed to the inhibition of metabolism. Possibly, because
it’s a different mechanism of action in the stresses, that would be the
difference in the activity of the sKATP channel.
Dr Beyersdorf. Second, Elrod and coworkers demonstrated in
an article in Circulation in 2008 that SUR1 KO mice are protected
against ischemia. Their experiments showed reduced infarct size
and preserved function after a surgical ligation of the left coronary
artery. Could you comment on a positive correlation between your
and their results?
Ms Sellitto. The SUR1 unit in the mouse model has been shown
to have heterozygotes found predominantly in the atria and not so
much in the ventricle. But in humans, SUR1 is more homogeneous,
so DZX could have an effect in preventing damage caused by ische-
mia in the human heart.diovascular Surgery c Volume 140, Number 5 1159
